Immune-Related Adverse Events of Cemiplimab Therapy in Advanced Cervical Cancer-Data from the Polish-Czech Cervical Cancer Immunotherapy Group (PCCIG-01) with a Review of the Literature.

Antibodies (Basel) · 2026 · PMC13214483 · PMID 42200833

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

showed a trendp = 0.07so close (0.05 < p ≤ 0.1)

Patients who developed thyroid irAEs showed a trend toward improved OS (log-rank p = 0.07; HR 0.45, 95% CI 0.19–1.08), which reached statistical significance after adjustment for predefined confounders (HR 0.40, 95% CI 0.17–0.98; p = 0.045).

also in 53,322 other papers

did not reach statistical significanceno p-value reported

For OS, a numerically longer OS was observed in patients with irAEs, although the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.